Vaccines and diagnostics for the ehrlichioses
US-10131705-B2 · Nov 20, 2018 · US
Vaccines and diagnostics for the ehrlichioses
US9850295B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9850295-B2 |
| Application number | US-201715440958-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 23, 2017 |
| Priority date | Jan 10, 2008 |
| Publication date | Dec 26, 2017 |
| Grant date | Dec 26, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated antibody that recognizes and immunologically binds to a polypeptide consisting of SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 8; SEQ ID NO: 9; SEQ ID NO: 10; or SEQ ID NO: 11, or an amino acid sequence that is at least 95% identical thereto, wherein the antibody is either bound to a solid support or a detectable label. 2. The antibody of claim 1 , wherein the antibody is a monoclonal antibody, is comprised in polyclonal antisera, or is an antibody fragment. 3. The antibody of claim 2 , wherein the antibody is a monoclonal antibody. 4. The antibody of claim 2 , wherein the antibody is comprised in polyclonal antisera. 5. The antibody of claim 1 , wherein the polypeptide consists of SEQ ID NO:3. 6. The antibody of claim 1 , wherein the polypeptide consists of SEQ ID NO:4. 7. The antibody of claim 1 , wherein the polypeptide consists of SEQ ID NO:8. 8. The antibody of claim 1 , wherein the polypeptide consists of SEQ ID NO:9. 9. The antibody of claim 1 , wherein the polypeptide consists of SEQ ID NO:10. 10. The antibody of claim 1 , wherein the polypeptide consists of SEQ ID NO:11. 11. The antibody of claim 1 , wherein the detectable label is a radioactive label, a fluorescent label, a chemiluminescent label, an enzyme label, or a paramagnetic label.
Assignees
Inventors
Classifications
Carrier-bound or immobilised peptides (carrier-bound or immobilised enzymes C12N11/00); Preparation thereof · CPC title
- C07K16/1246Primary
Rickettsiales (O) · CPC title
from Richettsiales (O) · CPC title
Antiparasitic agents · CPC title
from ticks · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9850295B2 cover?
- The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.
- Who is the assignee on this patent?
- Res Found Dev
- What technology area does this patent fall under?
- Primary CPC classification C07K16/1246. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).